The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.
Schulze
Thomas G
TG
Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-3719,USA. schulzet@mail.nih.gov
Alda
Martin
M
Adli
Mazda
M
Akula
Nirmala
N
Ardau
Raffaella
R
Bui
Elise T
ET
Chillotti
Caterina
C
Cichon
Sven
S
Czerski
Piotr
P
Del Zompo
Maria
M
Detera-Wadleigh
Sevilla D
SD
Grof
Paul
P
Gruber
Oliver
O
Hashimoto
Ryota
R
Hauser
Joanna
J
Hoban
Rebecca
R
Iwata
Nakao
N
Kassem
Layla
L
Kato
Tadafumi
T
Kittel-Schneider
Sarah
S
Kliwicki
Sebastian
S
Kelsoe
John R
JR
Kusumi
Ichiro
I
Laje
Gonzalo
G
Leckband
Susan G
SG
Manchia
Mirko
M
Macqueen
Glenda
G
Masui
Takuya
T
Ozaki
Norio
N
Perlis
Roy H
RH
Pfennig
Andrea
A
Piccardi
Paola
P
Richardson
Sara
S
Rouleau
Guy
G
Reif
Andreas
A
Rybakowski
Janusz K
JK
Sasse
Johanna
J
Schumacher
Johannes
J
Severino
Giovanni
G
Smoller
Jordan W
JW
Squassina
Alessio
A
Turecki
Gustavo
G
Young
L Trevor
LT
Yoshikawa
Takeo
T
Bauer
Michael
M
McMahon
Francis J
FJ
D018692:Antimanic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007391:International Cooperation; D018020:Lithium Compounds / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009315:National Institute of Mental Health (U.S.); D010597:Pharmacogenetics; D010641:Phenotype; D014481:United States
D018692:Antimanic Agents; D018020:Lithium Compounds
Pharmacogenomics J. 2009 Aug;9(4):225-33
19365399
Bipolar Disord. 2003 Apr;5(2):110-4
12680900
Bipolar Disord. 2008 Jun;10(4):495-502
18452445
Am J Hum Genet. 2006 May;78(5):804-814
16642436
Neuropsychopharmacology. 2008 Nov;33(12):2810-9
18288090
Mol Psychiatry. 2008 Feb;13(2):197-207
17486107
Psychol Med. 2008 Feb;38(2):289-300
17922940
Nat Rev Drug Discov. 2008 Oct;7(10):807-17
18806753
Am J Pharmacogenomics. 2005;5(1):53-62
15727489
Neuropsychopharmacology. 2002 Jul;27(1):105-19
12062911
Bioinformatics. 2003 Jan;19(1):149-50
12499305
Psychopharmacology (Berl). 2004 Aug;174(4):477-89
15243737
Eur J Hum Genet. 2009 Jul;17(7):946-57
19156168
Int Rev Psychiatry. 2007 Oct;19(5):523-30
17896232
Psychiatr Clin North Am. 2003 Jun;26(2):457-94, x
12778843
PLoS Med. 2007 Aug;4(8):e209
17696640
Am J Psychiatry. 2004 May;161(5):780-96
15121641
Schizophr Res. 2009 Jan;107(1):13-21
18930379
Schizophr Res. 1999 May 25;37(2):191-6
10374654
Arch Gen Psychiatry. 2007 Jun;64(6):689-97
17548750
Am J Psychiatry. 2006 Feb;163(2):217-24
16449474
Biol Psychiatry. 2008 Jun 15;63(12):1103-10
18191112
J Clin Psychiatry. 2002 Oct;63(10):942-7
12416605
Am J Psychiatry. 2007 Aug;164(8):1181-8
17671280
Pharmacogenomics J. 2004;4(1):40-8
14676821
Am J Psychiatry. 2009 Jun;166(6):718-25
19448189
J Affect Disord. 2007 Dec;104(1-3):185-90
17442400
Am J Psychiatry. 2007 Oct;164(10):1530-8
17898344
Nature. 2004 Apr 1;428(6982):486
15057820